Recently, investigators performed a proof-of-concept demonstration in primary human leukemic cells: disrupting STAG1 eliminated STAG2mut AML cells and was well tolerated by wild-type hematopoietic stem cells [80]. This evidence concerns the gene STAG1 and acute myeloid leukemia.